Patents
Literature
4 results about "Factor X" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Factor X, also known by the eponym Stuart–Prower factor, is an enzyme (EC 3.4.21.6) of the coagulation cascade. It is a serine endopeptidase (protease group S1, PA clan). Factor X is synthesized in the liver and requires vitamin K for its synthesis.
Bispecific Factor VIII mimetic antibody
ActiveCN115052898BImmunoglobulins against blood coagulation factorsBlood disorderAntiendomysial antibodiesFactor X
The present invention relates to bispecific antibodies that can bind to coagulation factor IX (FIX) and / or its activated form factor IXa (FIXa) and factor X (FX) and / or its activated form factor Xa (FXa) and promote the activation of FX by FIXa, as well as methods and compositions for treating subjects suffering from coagulopathy such as hemophilia A with or without inhibitors.
Owner:NOVO NORDISK AS
Method for preparing an irradiated platelet lysate
The invention relates to a method for preparing an irradiated platelet lysate, comprising the steps of providing a starting platelet lysate having platelet factors including growth factors and plasma proteins including coagulation factors and proteins other than the coagulation factors. Double irradiation of the starting platelet lysate, using UVC radiation and ionizing radiation. The double irradiation with UVC radiation and ionizing radiation being arranged to retain at least 75% of the total protein concentration of the starting platelet lysate, while reducing, by at least 40%, the concentration of at least one of the coagulation factors including fibrinogen, factor II, factor VII, factor IX, factor X and factor XI of the starting platelet lysate.
Owner:MACO PHARMA SA
Combination of factor vii and a Anti-factor ix and factor x bispecific antibody
A pharmaceutical composition comprising: a. transgenic Factor VII and b. a multispecific antibody directed against Factor IX and Factor X. The patent application contains 10 more claims.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA
High efficiency ISVD compounds capable of replacing FVIII (A)
PendingCN119630707AImprove oral bioavailabilityImmunoglobulins against blood coagulation factorsAntibody ingredientsOral medicationFactor X
The present invention provides ISVD polypeptide derivatives capable of binding to blood coagulation factor IX (a) and factor X (a), which are potent and provide sufficiently long half-lives, thereby allowing effective subcutaneous and oral administration. Thus, the ISVD polypeptide derivatives disclosed herein are suitable for treating hemophilia A, hemophilia A with inhibitors, and acquired hemophilia A by various routes of administration, including subcutaneous and oral administration.
Owner:NOVO NORDISK AS